Apotex Biosimilar Goes To FDA, But May Enter Crowded Market
This article was originally published in The Pink Sheet Daily
Executive Summary
Pegfilgrastim product, a collaboration with the Indian firm Intas, may have to compete with multiple filgrastim products, along with its reference biologic, Amgen’s Neulasta.